Search

everythinglearnresearchcommunity

for

Search:↓

PRP treatments have been effective for the user, with a new recommendation of using a high-quality plasma kit once a year. The user seeks experiences with this specific PRP approach.

The user has been taking oral Finasteride and topical Essengen 6 Plus for hair loss and is experiencing increased depression. They plan to get bloodwork to check hormone levels and are seeking advice on which tests to include.

The conversation discusses scalp itching and tenderness after microneedling, despite using medicated shampoos and proper sanitation. The user plans to see a dermatologist and is concerned about possible infection or allergic reaction.

A user is seeking a titanium dioxide-free finasteride pill due to health concerns. They have not found a suitable supplier yet.

A human trial involving verteporfin for hair regeneration, with the results showing some regrowth of 1-2 hairs in an area where a follicular unit was extracted. The conversation also suggested that future studies should involve higher doses and more frequent injections.

Low testosterone and estradiol may contribute to hair loss, and blocking DHT without sufficient hormone levels might hinder regrowth. The discussion highlights the importance of hormone balance, with some considering supplements and lifestyle changes to support hair health.

Hair loss treatments including Minoxidil, Finasteride and RU58841; with a focus on Pyrilutamide could potentially be used as an effective treatment.

Concerns about a potential ban on finasteride and dutasteride due to side effects, with users advocating for continued access and informed choice. Alternative treatments like pyrilutamide are also mentioned.

The user is experiencing diffuse androgenic alopecia and is trying various treatments, including 5mg finasteride, loniten, and Formula 82D, which contains dutasteride, a steroid, and tretinoin. They report potential regrowth with Formula 82D, despite previous treatments being ineffective.

The conversation discusses the use of topical finasteride from Hasson and Wong, with claims that none of their 800 users reported side effects. The user expresses skepticism about these claims and seeks others' experiences with the treatment.

Kintor's Pyrilutamide results for hair loss treatment will be released soon. The treatment may replace current treatments like finasteride and minoxidil without systemic side effects.

A 23-year-old experienced severe depression and suicidal thoughts from oral finasteride and is considering trying topical finasteride but is worried about similar side effects. They are currently using RU58841 and Minoxidil and are seeking advice on the lowest effective dose of topical finasteride.

The user has been using dutasteride and finasteride but still experiences hair loss and high DHT levels. They plan to try topical finasteride and RU58841 while continuing dutasteride to see if topicals are more effective.

Treatments used to prevent and treat male pattern baldness, the difficulty in finding a permanent cure for hair loss, and the potential financial motivations of companies not wanting to find a cure.

A 22-year-old female with AGA due to PCOS is using 5% minoxidil foam and 2mg finasteride daily, and is seeking advice on microneedling frequency and safety. Concerns about finasteride dosage and its effects on PCOS were discussed, with emphasis on trusting the prescribed treatment plan.

The conversation discusses using peptides BPC-157 and TB-500, combined with microneedling, to potentially enhance hair regrowth. The user plans to try BPC-157 due to its lower cost and reports of hair growth, despite limited human trials and concerns about side effects from other treatments like minoxidil and finasteride.

Trans woman experiencing thinning hair despite low testosterone and finasteride use seeks possible causes and solutions. Current treatments include finasteride, spironolactone, estradiol, vitamins, and microneedling; minoxidil not tried due to concerns about dependence and side effects.

Verteporfin human clinical trials for hair loss may start in 2025. Additional resources and presentations are available for more information.

Pyrilutamide is considered by some as an alternative for those avoiding 5AR inhibitors like finasteride and dutasteride, but opinions on its effectiveness vary. Some users report similar results with fluridil and pyrilutamide, while others find pyrilutamide less effective compared to prescription treatments.

The user experienced significant hair thinning despite using finasteride and minoxidil, leading to concerns about whether it's a temporary shed or a more serious issue. They plan to start using RU58841 and are advised to consult a doctor to rule out other causes like autoimmune disorders.

Increased Malassezia and Cutibacterium in the scalp microbiome are linked to higher sebum production and inflammation in androgenetic alopecia (AGA). Treatments include ciclopirox shampoo, benzoyl peroxide shampoo, clobetasol propionate, calcipotriol, minoxidil, finasteride, and dutasteride.

New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.

First patient dosed with Pyrilutamide (Kintor) Phase III for hair loss treatment. Pyrilutamide differs from approved treatments as it competes with DHT to bind hair follicles, potentially reducing side effects.

Apply tretinoin at night and minimize sun exposure. Use sunscreen as a last resort due to its messiness and need for frequent reapplication.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.

Potential success with the hair loss treatment Pyrilutamide, and possible group buying opportunities for it along with other treatments such as Finasteride and Minoxidil.

The user is considering using dutasteride or finasteride for hair loss and has recurrent folliculitis. Another user suggests treating the folliculitis and notes diffuse thinning.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

Users discuss finding reliable sources for RU58841, focusing on lab tests, batch consistency, and community reputation. Some mention using alternatives like pyrilutamide.